Back to results

CompletedPhase 2

Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease

NCT01018875

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Site Reference ID/Investigator# 22687

Kazan', Russia

+20 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2009-12
Enrollment: 242 participants
Sponsor: AbbVie (prior sponsor, Abbott)
Purpose: treatment

Locations (21)

Site Reference ID/Investigator# 22687Kazan', Russia
Site Reference ID/Investigator# 22636Moscow, Russia
Site Reference ID/Investigator# 23702Moscow, Russia
Site Reference ID/Investigator# 22635Saint Petersburg, Russia
Site Reference ID/Investigator# 22633Saint Petersburg, Russia
Site Reference ID/Investigator# 22637Saint Petersburg, Russia
Site Reference ID/Investigator# 22632Saint Petersburg, Russia
Site Reference ID/Investigator# 22634Saint Petersburg, Russia
Site Reference ID/Investigator# 24563Saint Petersburg, Russia
Site Reference ID/Investigator# 22689Saratov, Russia
Site Reference ID/Investigator# 22630Dnipro, Ukraine
Site Reference ID/Investigator# 22625Donetsk, Ukraine
Site Reference ID/Investigator# 22624Hlevakha, Ukraine
Site Reference ID/Investigator# 22629Kharkiv, Ukraine
Site Reference ID/Investigator# 24565Kherson, Ukraine
Site Reference ID/Investigator# 24566Kiev, Ukraine
Site Reference ID/Investigator# 22622Kiev, Ukraine
Site Reference ID/Investigator# 22623Kiev, Ukraine
Site Reference ID/Investigator# 22628Luhansk, Ukraine
Site Reference ID/Investigator# 43143Odesa, Ukraine
Site Reference ID/Investigator# 22627Poltava, Ukraine

Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease — TrialFind